Laboratory Co. of America Holdings (NYSE:LH) Shares Purchased by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC boosted its holdings in Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 132.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,056 shares of the medical research company's stock after buying an additional 1,742 shares during the quarter. Kestra Private Wealth Services LLC's holdings in Laboratory Co. of America were worth $701,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. SouthState Corp purchased a new stake in shares of Laboratory Co. of America during the 3rd quarter valued at about $28,000. Horizon Bancorp Inc. IN purchased a new stake in shares of Laboratory Co. of America during the 3rd quarter valued at about $29,000. Fortitude Family Office LLC increased its position in shares of Laboratory Co. of America by 312.5% during the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company's stock valued at $30,000 after purchasing an additional 100 shares during the last quarter. Riverview Trust Co increased its position in shares of Laboratory Co. of America by 172.6% during the 3rd quarter. Riverview Trust Co now owns 169 shares of the medical research company's stock valued at $38,000 after purchasing an additional 107 shares during the last quarter. Finally, Concord Wealth Partners increased its position in shares of Laboratory Co. of America by 43.3% during the 3rd quarter. Concord Wealth Partners now owns 172 shares of the medical research company's stock valued at $38,000 after purchasing an additional 52 shares during the last quarter. Hedge funds and other institutional investors own 95.94% of the company's stock.

Laboratory Co. of America Price Performance

Shares of NYSE LH traded down $0.51 during midday trading on Tuesday, reaching $245.98. 66,696 shares of the stock traded hands, compared to its average volume of 590,038. The stock has a market capitalization of $20.57 billion, a PE ratio of 27.89, a P/E/G ratio of 1.84 and a beta of 1.07. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.44 and a quick ratio of 1.30. Laboratory Co. of America Holdings has a one year low of $191.97 and a one year high of $258.59. The company's 50 day moving average is $237.63 and its 200 day moving average is $231.23.

Laboratory Co. of America (NYSE:LH - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. On average, equities research analysts anticipate that Laboratory Co. of America Holdings will post 15.96 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Thursday, February 27th. Laboratory Co. of America's payout ratio is currently 32.65%.

Insider Activity at Laboratory Co. of America

In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 1,000 shares of the firm's stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $239.42, for a total value of $239,420.00. Following the completion of the sale, the executive vice president now owns 2,670 shares of the company's stock, valued at approximately $639,251.40. This trade represents a 27.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Glenn A. Eisenberg sold 11,711 shares of the firm's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $240.43, for a total value of $2,815,675.73. Following the completion of the sale, the executive vice president now directly owns 31,289 shares of the company's stock, valued at approximately $7,522,814.27. This represents a 27.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,504 shares of company stock valued at $5,905,692 over the last quarter. 0.85% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently commented on LH. Hsbc Global Res raised shares of Laboratory Co. of America from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, October 30th. Barclays reduced their target price on shares of Laboratory Co. of America from $271.00 to $260.00 and set an "equal weight" rating for the company in a report on Friday, February 7th. UBS Group reduced their target price on shares of Laboratory Co. of America from $293.00 to $286.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Piper Sandler increased their target price on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Finally, Jefferies Financial Group increased their target price on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Laboratory Co. of America presently has a consensus rating of "Moderate Buy" and a consensus price target of $265.31.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.